Drug Profile
Pritumumab - Nascent Biotech
Alternative Names: ACA 11; CLN-IgG; CLNH 11; Monoclonal antibody ACA 11Latest Information Update: 13 Feb 2024
Price :
$50
*
At a glance
- Originator University of California, San Diego
- Developer Nascent Biotech
- Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Glioma
- Phase I Brain cancer
- Research COVID 2019 infections
- No development reported Pancreatic cancer
Most Recent Events
- 29 Nov 2023 Nascent Biotech receives Notice of Allowance for a Method of Use patent for pritumumab in Japan
- 22 Aug 2023 US FDA approves the protocol to initiate a phase II trial for brain cancer
- 13 Jun 2023 Efficacy, adverse events and pharmacokinetics data from phase I trial in Brain cancer presented at American Society of Clinical Oncology (ASCO-2023)